Abstract
New drugs are urgently needed for the treatment of tropical parasitic diseases such as leishmaniasis and human African trypanosomiasis (HAT). This work involved a high-throughput screen of a focussed kinase set of similar to 3400 compounds to identify potent and parasite-selective inhibitors of an enzymatic Leishmania CRK3-cyclin 6 complex. The aim of this study is to provide chemical validation that Leishmania CRK3-CYC6 is a drug target. Eight hit series were identified, of which four were followed up. The optimisation of these series using classical SAR studies afforded low-nanomolar CRK3 inhibitors with significant selectivity over the closely related human cyclin dependent kinase CDK2.
| Original language | English |
|---|---|
| Pages (from-to) | 2214-2224 |
| Number of pages | 11 |
| Journal | ChemMedChem |
| Volume | 6 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - 9 Dec 2011 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- CRK3
- cyclin-dependent cdc2-related kinases
- leishmaniasis
- triazolopyridines
- ureas
- CYCLIN-DEPENDENT KINASE
- TRYPANOSOMA-BRUCEI
- 3-AMINOPYRAZOLE INHIBITORS
- ANTITUMOR AGENTS
- DISCOVERY
- MEXICANA
- DISEASES
Fingerprint
Dive into the research topics of 'Identification of Inhibitors of the Leishmania cdc2-Related Protein Kinase CRK3'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver